We suggest treatment with anticoagulation for 3 months over extended therapy if there is a low or moderate bleeding risk (Grade 2B), and recommend treatment for 3 months over extended therapy if there is a high risk of bleeding (Grade 1B). Remarks: In all patients who receive extended anticoagulant therapy, the continuing use of treatment should be reassessed at periodic intervals (eg, annually). DISCLAIMER: American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at http://www.chestnet. org/Guidelines-and-Resources/Guidelines-and-Consensus-Statements/ CHEST-Guidelines. FUNDING/SUPPORT: This guideline was supported solely by internal funds from The American College of Chest Physicians. ENDORSEMENTS: This guideline is endorsed by the American Asso- ciation for Clinical Chemistry, the American College of Clinical Pharmacy, the International Society for Thrombosis and Haemostasis, and the American Society of Health-System Pharmacists. CORRESPONDENCE TO: Elie A. Akl, MD, MPH, PhD, Department of Internal Medicine, Faculty of Medicine, American University of Beirut, PO Box 11-0236, Riad-El-Solh Beirut 1107 2020, Lebanon; e-mail: Copyright 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. 316 Evidence-Based Medicine [ 1 4 9 # 2 C H E S T F E B R U A R Y 2 0 1 6 ] 7. 